# Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia

> **NCT06610760** · PHASE4 · RECRUITING · sponsor: **Yongquan Shi** · enrollment: 196 (estimated)

## Conditions studied

- Gastric Intestinal Metaplasia

## Interventions

- **DRUG:** Ursodeoxycholic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06610760
- **Lead sponsor:** Yongquan Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610760, "Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT06610760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*